FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to humanized antibody against basigin or its antigen-binding fragment. A molecule of isolated nucleic acid coding the specified antibody, an expression vector containing the specified molecule of nucleic acid, a host cell containing the specified vector, and a composition containing the specified antibody are also disclosed. A method for treatment using the specified antibody and use of the specified antibody for preparing a drug for treating a disease associated with basigin are disclosed.
EFFECT: invention has the ability to treat effectively diseases associated with basigin.
26 cl, 8 dwg, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
